Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Open Label Prospective Dose-Ranging Clinical Trial with Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the Treatment of Hospitalized Patients with Steroid-Refractory Acute Graft-versus-Host Disease

Next Previous
Search
Trial Profile

Phase 2 Open Label Prospective Dose-Ranging Clinical Trial with Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the Treatment of Hospitalized Patients with Steroid-Refractory Acute Graft-versus-Host Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegtarazimod (Primary) ; Ruxolitinib
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AURORA
  • Sponsors ReAlta Life Sciences

    • Most Recent Events

    • 31 Jan 2025 Planned End Date changed from 1 Sep 2025 to 1 Dec 2025.
    • 31 Jan 2025 Planned primary completion date changed from 1 Apr 2025 to 1 Oct 2025.
    • 05 Nov 2024 According to a ReAlta Life Sciences media release, this trial is currently enrolling at clinical sites located within the United States, Germany and Spain.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top